Gilead sales and marketing update

Gilead recalled two lots of HIV drug Atripla emtricitabine/tenofovir/ efavirenz due to the presence of red silicone rubber particulates. Gilead said the lots, which include about 40,000 bottles total, were distributed to pharmacies in the U.S. The company said it has adequate supply of Atripla and of the API to ensure ongoing, uninterrupted access. Gilead, which recorded sales of $3.6 billion for Atripla in 2013, said it is not aware of any complaints attributable to the particulates. ...